These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19668166)

  • 1. Signs of life in Q2.
    Yang W
    Nat Biotechnol; 2009 Aug; 27(8):686. PubMed ID: 19668166
    [No Abstract]   [Full Text] [Related]  

  • 2. When times get tough.
    Jong S
    Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmas partner in venture seeking drug discovery tools.
    Mack GS
    Nat Biotechnol; 2008 Sep; 26(9):960-1. PubMed ID: 18779790
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotechnology mergers and acquisitions.
    Champsi FH
    Nat Biotechnol; 1998 May; 16 Suppl():61-2. PubMed ID: 9591276
    [No Abstract]   [Full Text] [Related]  

  • 5. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do you measure "success" in a biotechnology company?
    Greetham EM
    Nat Biotechnol; 1998 May; 16 Suppl():59-60. PubMed ID: 9591275
    [No Abstract]   [Full Text] [Related]  

  • 7. BioXell: an Italian biotech success story?
    Sheridan C
    Nat Biotechnol; 2006 Sep; 24(9):1045-6. PubMed ID: 16964198
    [No Abstract]   [Full Text] [Related]  

  • 8. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 9. A venture capital view of challenges, opportunities, and innovation in biomedical research.
    Ratcliffe LT
    Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genentech grapples with direct offer.
    Huggett B
    Nat Biotechnol; 2009 Mar; 27(3):212. PubMed ID: 19270652
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotechnology. Mixed reactions to merger.
    Gershon D
    Nature; 1990 Feb; 343(6260):681. PubMed ID: 2304541
    [No Abstract]   [Full Text] [Related]  

  • 12. PEGging biotech growth.
    Jacobs T
    Nat Biotechnol; 2006 May; 24(5):506. PubMed ID: 16680127
    [No Abstract]   [Full Text] [Related]  

  • 13. The hermit crab solution.
    Silverman E
    Nat Biotechnol; 2006 Mar; 24(3):245-7. PubMed ID: 16680810
    [No Abstract]   [Full Text] [Related]  

  • 14. Financing biotechnology in an inefficient market.
    Purcell DJ
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE31-2. PubMed ID: 10052324
    [No Abstract]   [Full Text] [Related]  

  • 15. The changing attitude of European VCs.
    Mitchell P
    Nat Biotechnol; 2004 Apr; 22(4):479. PubMed ID: 15085807
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotech on pace for record year.
    Yang W
    Nat Biotechnol; 2011 Sep; 29(9):780. PubMed ID: 21904312
    [No Abstract]   [Full Text] [Related]  

  • 17. Valuation with cash multiples.
    Booth BL
    Nat Rev Drug Discov; 2005 Jul; 4(7):533-4. PubMed ID: 16075485
    [No Abstract]   [Full Text] [Related]  

  • 18. Australia: ready for business.
    Woodrow GC; Nisbet I; Corbett ME
    Nat Biotechnol; 1997 Aug; 15(8):731-2. PubMed ID: 9255783
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotechnology company's shares dive 67% after drug failure.
    Dobson R
    BMJ; 2000 Oct; 321(7268):1039. PubMed ID: 11053161
    [No Abstract]   [Full Text] [Related]  

  • 20. Taiwan biotech buoyed by colossal financings.
    Cyranoski D
    Nat Biotechnol; 2014 Jun; 32(6):508-10. PubMed ID: 24911482
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.